22nd week of 2010 patent applcation highlights part 39 |
Patent application number | Title | Published |
20100135885 | System and Method for Removing Organic Compounds from Exhaust Gases - A system removes ethanol and other organic carbons from fermentation exhaust gases. Structurally, the system includes a first scrubber with top and bottom ends. Further, the system includes a second scrubber with a top end and with a bottom end in fluid communication with the first scrubber's top end. During operation, exhaust gases are introduced into the bottom end of the first scrubber. Further, a light alcohol solvent is flowed down from the top end to the bottom end of the first scrubber. As the solvent contacts the exhaust gases, it absorbs the other organic carbons. Thereafter, the exhaust gases enter the second scrubber's bottom end. At the second scrubber's top end, water is introduced and falls into contact with the exhaust gases, absorbing the ethanol. In this manner, ethanol and other organic carbons are removed from the exhaust gases solely through absorption by solvents. | 2010-06-03 |
20100135886 | Treatment of Talc in a Solvent - The present invention is directed to a process for the treatment of talc, comprising the steps of (a) providing a talc having a first brightness value B1, measured according to ISO 2469, and forming a suspension of the talc in a liquid phase, the liquid phase of the suspension comprising at least one organic solvent, (b) delaminating and/or reducing the weight median particle size d | 2010-06-03 |
20100135887 | MODIFIER FOR SILICATE-CONTAINING FIBROUS MATERIAL, METHOD FOR MODIFYING SILICATE-CONTAINING FIBROUS MATERIAL, AND MODIFIED MATERIAL - This invention is intended to modify, detoxify, or effectively use, as cordierite, a silicate-containing fibrous material. A silicate-containing fibrous material is modified into a low-expansion and heat-resistant cordierite compound by treating a silicate-containing fibrous material with a modifier for a silicate-containing fibrous material comprising an aqueous alkaline solution mainly composed of alkali silicate comprising an ammonium ion, a halide ion, a boron ion, and an aluminum ion. | 2010-06-03 |
20100135888 | Purification of Silicon by Electric Induction Melting and Directional Partial Cooling of the Melt - The present invention is apparatus for, and method of, purification of silicon by electric induction heating and melting of silicon in a crucible or susceptor vessel, with subsequent directional partial cooling of the silicon melt to an initial amorphous-to-crystalline (solidification) temperature to produce a directionally solidified purified quantity of silicon and a separate quantity of high impurity silicon. The quantity of high impurity silicon is removed from the vessel and the purified quantity of silicon at solidification temperature is remelted in the vessel for removal from the vessel or further processing. | 2010-06-03 |
20100135889 | Purification of Materials Non-Electrically Conductive in the Solid State and Electrically Conductive in the Molten State with Electric Induction Power - The present invention is apparatus for, and method of, heating, melting and purifying a material by electric induction heating in a susceptor furnace. Non-electrically conductive solid charge may initially be placed in the furnace. Output frequency from a power source supplying current to one or more induction coils surrounding the furnace is selected to maximize magnetic coupling with the susceptor material in the susceptor furnace to induce eddy current heating in the material. Heat transfers by conduction from the susceptor material to the non-electrically conductive charge placed in the susceptor furnace to melt the charge. Output frequency is reduced as the charge melts and becomes electrically conductive to enhance magnetic coupling with the melt in the furnace. Degassing of impurities from the melt can be achieved by bubbling a gas through the melt while the surface level of the melt is maintained at vacuum. Degassing is enhanced by creating an electromagnetic ripple/wave action that increases the surface area of the melt during the degassing process. | 2010-06-03 |
20100135890 | Method to Produce Light-Emitting Nano-Particles of Diamond - Method to produce diamonds containing Nitrogen-Vacancy centres from diamonds grown by a high pressure and high temperature process and containing isolated substitutional nitrogen, comprising: —Irradiating ( | 2010-06-03 |
20100135891 | PROCESS FOR PRODUCTION OF PCC - The present invention relates to a process of preparing precipitated calcium carbonate (PCC) in a low energy intensity reactor in such a manner that the amount of solids in the PCC product can be raised to 35% or more without performing a dewatering step. The process comprises performing in parallel and in two or more separate reaction vessel the steps of contacting calcium hydroxide with a gas comprising carbon dioxide to allow formation of calcium carbonate, and adding calcium oxide, lime or dry calcium hydroxide or a combination of any of the three to a part of the resulting mixture of calcium hydroxide and calcium carbonate. The invention further provides a specialized reactor system as well as the use of this reactor system in the manufacture of PCC. | 2010-06-03 |
20100135892 | ABSORPTION METHOD FOR RECOVERING GAS CONTAMINANTS AT HIGH PURITY - Solvent absorption processes for separating components of an impure feed gas are disclosed. The processes involve two stages of gas-liquid contacting, namely a first, absorption stage and a second, stripping stage. In the case of a carbon dioxide (CO | 2010-06-03 |
20100135893 | CARBON NANORINGS MANUFACTURED FROM TEMPLATING NANOPARTICLES - Methods for manufacturing carbon nanostructures include 1) forming intermediate carbon nanostructures by polymerizing a carbon precursor in the presence of templating nanoparticles, 2) carbonizing the intermediate carbon nanostructures to form an intermediate composite nanostructure, and 3) removing the templating nanoparticles from the intermediate composite nanostructure to form carbon nanorings. The carbon nanorings manufactured using the foregoing steps have one or more carbon layers forming a wall that defines a generally annular nanostructure having a hole. The length of the nanoring is less than or about equal to the outer diameter thereof. The carbon nanostructures are well-suited for use as a fuel cell catalyst support. The carbon nanostructures exhibit high surface area, high porosity, high graphitization, and facilitate mass transfer and electron transfer in fuel cell reactions. Carbon nanorings manufactured according to the present invention can be used as a substitute for more expensive and likely more fragile carbon nanotubes. | 2010-06-03 |
20100135894 | METHOD OF PRODUCING CHLORINE DIOXIDE, AND ALKALINE COMPOSITION FOR CHLORINE DIOXIDE PRODUCTION TO BE USED IN THE METHOD - Disclosed is a method for producing chlorine dioxide using hypochlorite, chlorite and an acidic substance, wherein sodium hypochlorite and sodium chlorite are mixed together in advance, and then hydrochloric acid is added into the mixture liquid. | 2010-06-03 |
20100135895 | Process for Purifying HBr in Hydrocarbons - The present invention provides a method for separating HBr from HBr-containing hydrocarbons (alkenes, aromatics and/or alkanes) to purify the hydrocarbons. Reacting a silica supported metal oxide solid material (MO | 2010-06-03 |
20100135896 | SIMULTANEOUS WARM GAS DESULFURIZATION AND CO-SHIFT FOR IMPROVED SYNGAS CLEANUP - The present invention involves a process and materials for simultaneous desulfurization and water gas shift of a gaseous stream comprising contacting the gas stream with a nickel aluminate catalyst. The nickel aluminate catalyst is preferably selected from the group consisting of Ni | 2010-06-03 |
20100135897 | SPHERICAL TRICOBALT TETRAOXIDE AND METHOD OF PREPARING THE SAME - A method of preparation of spherical tricobalt tetraoxide, including at least oxidizing a bivalent cobalt salt in a wet environment and in the presence of a precipitant, a complexing agent, and an oxidant to yield spherical cobalt oxyhydroxide.cobalt hydroxide according to the following equation Co | 2010-06-03 |
20100135898 | METHOD FOR PRODUCING METAL HYDRIDE - Disclosed is a method for producing a metal hydride, which enables to obtain a metal hydride from a metal imide or a metal amide. Specifically, in an air current containing a hydrogen gas having a hydrogen partial pressure of 0.1 MPa or greater, hydrogen is reacted with one or both of a metal imide and a metal amide, thereby producing a metal hydride. The metal constituting the metal amide and the metal imide is preferably lithium, sodium or potassium. | 2010-06-03 |
20100135899 | PROCESS FOR RELEASING HYDROGEN GAS - A process for releasing hydrogen gas is disclosed. The process comprises the step of irradiating hydrogen storage particles dispersed within thermal promoter particles under conditions to release said hydrogen from said hydrogen storage particles. A system for implementing the process as well as uses for the hydrogen gas released from the above process are disclosed. | 2010-06-03 |
20100135900 | CD37 IMMUNOTHERAPEUTIC COMBINATION THERAPIES AND USES THEREOF - The present disclosure provides methods for using CD37-specific binding molecules (such as a CD37-specific SMIP or antibody) in combination with mTOR inhibitors (such as rapamycin and derivatives or analogues thereof) or phosphatidylinositol 3-kinase (PI3K) inhibitors (such as p110δ-specific inhibitors or the like), which can be done concurrently or sequentially, to treat or prevent a B-cell related hyperproliferative disease, such as a lymphoma, carcinoma, myeloma, or the like. | 2010-06-03 |
20100135901 | COMBINATION THERAPY - The invention provides combination treatments with IL-21, analogues and derivatives thereof. | 2010-06-03 |
20100135902 | PAPILLOMAVIRUS PSEUDOVIRUSES FOR DETECTION AND THERAPY OF TUMORS - Disclosed herein are methods of detecting tumors, monitoring cancer therapy, and selectively inhibiting the proliferation and/or killing of cancer cells utilizing a papilloma pseudovirus or a papilloma virus-like particle (VLP) | 2010-06-03 |
20100135903 | USE OF A DNA DAMAGING AGENT AND A LIGAND FOR THE TREATMENT OF CANCER - The present invention relates generally to a method of treating a neoplastic condition and to agents useful for same. More particularly, the present invention is directed to a method of facilitating the treatment of a metastatic neoplastic tumour in a localised manner by effecting the exposure of neoplastic cell intra-cellular molecules, preferably intra-nuclear molecules, suitable for use as a therapeutic target. The co-localisation of tumour cells and metastases to discrete tissue locations thereby renders the method of the present invention useful in terms of the delivery of bystander-based therapy. | 2010-06-03 |
20100135904 | COMPOSITIONS AND METHODS FOR THE INHIBITION OF CRIPTO / GRP78 COMPLEX FORMATION AND SIGNALING - The present invention provides methods compositions and methods for treating a hyperproliferative disease comprising disrupting Cripto/GRP78 complex formation in a hyperproliferative cell. In certain embodiments, an antibody and/or siRNA may be used to inhibit Cripto/GRP78 binding, optionally coupled with other cancer therapies. Also provided are methods for identifying therapeutic compounds which can selectively inhibit Cripto/GRP78 binding. | 2010-06-03 |
20100135905 | ASSESSMENT OF CANCER SUSCEPTIBILITY TO MOLECULAR TARGETED THERAPY BY USE OF RECOMBINANT PEPTIDES - A method for assessing cancer susceptibility to molecular targeted therapy. Also provided are methods for in vivo panning of diverse molecules for isolation of targeting ligands that specifically bind an apoptotic cell associated with a responding tumor, targeting ligands identified by the panning methods, and diagnostic and imaging uses therefor. | 2010-06-03 |
20100135906 | IN VIVO IMAGING OF SULFOTRANSFERASES - Radiolabeled tracers for sulfotransferases (SULTs), their synthesis, and their use are provided. Included are substituted phenols, naphthols, coumarins, and flavones radiolabeled with | 2010-06-03 |
20100135907 | Oral Drug Compliance Monitoring Using Sound Detection - A tablet, pill or capsule containing a material which produces sound waves when the tablet, pill or capsule is exposed to the gastrointestinal system. A two step method for oral drug compliance monitoring. The first step is to ingest a tablet, pill or capsule containing a material which produces sound waves when the tablet, pill or capsule is exposed to the gastrointestinal system of a person. The second step is to detect the sound waves produced when the tablet, pill or capsule is exposed to the gastrointestinal system to confirm that the person has ingested the tablet, pill or capsule. | 2010-06-03 |
20100135908 | Delivery devices for modulating inflammation - Certain embodiments disclosed relate to compositions, including therapeutic compositions, methods, devices, and systems that modulate at least one inflammatory response or reaction. According to various embodiments, the compositions, methods, devices, and systems relate to modulating one or more of Toll-like receptors, Src family kinases, NF-kB molecules, proteases, or proteasomes. | 2010-06-03 |
20100135909 | DENDRIMERS AND METHODS OF MAKING AND USING THEREOF - A metal treatment composition including Tin (II) Chloride and processed montmorillonite clay. The addition of Tin (II) Chloride to the composition provides Tin for forming a ceramic-metal layer on the surfaces of the friction pair. Tin (II) Chloride provides Chlorine ions for forming Chloric films for protecting juvenile surfaces which form in the friction zone. The clay is heated and pulverized to produce a powder comprising both particles having crystalline layer structure and salts and oxides. The layered crystalline structure of the clay contains slip planes that transversely shift when tangential pressure from the friction pair is applied thereby lubricating the friction pair. The salts and oxides contribute to the formation of the ceramic-metal layer. | 2010-06-03 |
20100135910 | Modulation of Anergy and Methods for Isolating Anergy-Modulating Compounds - The present invention provides methods for identifying compounds capable of modulating anergy by inhibiting the production or activity of anergy associated E3 ubiquitin ligases or by altering the interaction between a ligase and its substrate. | 2010-06-03 |
20100135911 | SPATIAL EVOLUTION OF NEURAL ACTIVITY - A method for identifying a candidate drug includes administering a test compound to test subjects and having the test subjects perform a sustained task. A first evolution of neural activity in the test subjects is then determined and compared with a second evolution of neural activity. This second evolution of neural activity is obtained from control subjects performing the sustained task in the absence of the test compound. The test compound is then designated to be a candidate drug when a difference between the first and second evolutions of neural activity is above a difference threshold. | 2010-06-03 |
20100135912 | MAGNETOTACTIC BACTERIA MRI POSITIVE CONTRAST ENHANCEMENT AGENT AND METHODS OF USE - Magnetic resonance imaging (MRI) is enhanced by contrast agents such as superparamagnetic iron-oxide (SPIO) particles that resemble magnetite particles produced by magnetotactic bacteria. | 2010-06-03 |
20100135913 | Ionic and Non-Ionic Radiographic Contrast Agents for Use in Combined X-ray and Nuclear Magnetic Resonance Diagnostics - The invention concerns a method for obtaining diagnostic images of a human or animal body organ, region, fluid or tissue by using combined X-ray and/or Magnetization Transfer (MT) based MRI techniques and iodinated radiographic compounds as contrast agents, as well as improved Chemical Exchange dependent Saturation Transfer (CESDT or CEST) based MRI procedures in which a iodinated contrast agents is used for in vivo determining a physiological parameter of diagnostic interest. | 2010-06-03 |
20100135914 | AZEOTROPIC FUMIGANT COMPOSITIONS AND METHODS OF CONTROLLING PESTS - A fumigant composition including an azeotropic mixture of methyl iodide and sulfuryl fluoride; and a method of controlling at least one target insect species including treating a target space with a composition including an azeotropic mixture of methyl iodide and sulfuryl fluoride by applying an amount of the composition to the target space that is effective to kill a substantial portion of the target insect species in multiple development stages. | 2010-06-03 |
20100135915 | FOAM MATERIAL FOR MEDICAL USE AND METHOD FOR PRODUCING SAME - An in situ forming foam for medical applications and a method for making same is described, the method comprising the steps of: preparing a first component, Composition A, comprising an acidic solution of a polycationic polymer selected from the group comprising polymeric amines and polysaccharides; preparing a second component, Composition B, selected from the group comprising a metal carbonate, a metal bicarbonate or a mixture of a metal carbonate and a metal bicarbonate; maintaining said first and second components separately prior to mixing; and mixing said first and second components at an intended site of application. The foam is a mechanically robust but flexible and resilient material wherein the degree and nature of the porosity may be controlled. | 2010-06-03 |
20100135916 | Water in silicone emulsions containing elastomers - Water in silicone emulsions, methods for preparing the emulsions, and personal care products containing the emulsions are disclosed. The silicone phase of the water in silicone emulsions contains an emollient, a silicone elastomer containing a hydrophilic group, and an optional nonionic surfactant. The aqueous phase contains an anionic surfactant at such a concentration to provide a weight ratio of the silicone elastomer to anionic surfactant ranging from 60/1 to 1/1 in the water in silicone emulsion. The resulting water in silicone emulsions can be used in a variety of personal care, household and health care formulations, and in particular for sprayable lotions. | 2010-06-03 |
20100135917 | COSMETICALLY USED CROSS-LINKED METHYL METHACRYLATE-COPOLYMER - The present invention relates to cosmetic preparations which comprise at least one polymer A which comprises, in copolymerized form, methyl methacrylate, methacrylic acid, acrylic acid, if appropriate at least one compound with at least two free-radically polymerizable, olefinically unsaturated double bonds, and if appropriate further olefinically unsaturated compounds, with the proviso that the amount by weight of the methacrylic acid is at least equal to the amount by weight of the acrylic acid. | 2010-06-03 |
20100135918 | COPOLYMERS FOR COSMETIC APPLICATIONS - The present invention relates to aqueous skin or hair cosmetic preparations which comprise at least one polymer A which comprises, in copolymerized form, at least one ester of (meth)acrylic acid, at least one olefinically unsaturated, free-radically polymerizable anionogenic or anionic compound, at least one free-radically polymerizable olefinically unsaturated urethane-group-containing compound which comprises no silicone groups and, if appropriate, further free-radically polymerizable compounds. | 2010-06-03 |
20100135919 | PROTEOLYTIC ENZYME FORMULATIONS - Preferred embodiments of the present invention relate to proteolytic enzyme formulations. More specifically, several embodiments relate a proteolytic formulation comprising fungal protease, papain, bromelain, fungal pancreatin, nattokinase, protease-S, amylase, lipase, rutin, ginger, and CMIK-pH, to facilitate digestion, metabolism, degradation of target compounds, and systemic enzymatic action. | 2010-06-03 |
20100135920 | METHOD TO TREAT PROPOLIS - A method to treat propolis includes conducting at least one first extraction of propolis performed on a batch of raw propolis with a first pure solvent to obtain a first extract having first properties. A second extraction may be performed with a second different pure solvent on the filtration residues obtained after the first extraction, so as to collect and make usable the entirety of the components of propolis using organic solvents only; and finally the method may include a third extraction following after the second extraction, performed on the filtration residues obtained after this second extraction, using a third pure solvent different from the two others; the first solvent then being water, the second being alcohol and the third being oil. The method applies to the production of extracts of propolis for use in the manufacture of hygiene, care, cosmetic products, food products and food supplements. | 2010-06-03 |
20100135921 | Oral Care Compositions with Improved Aesthetics and Fused Silica - An oral care composition comprising fused silica and a flavoring agent. | 2010-06-03 |
20100135922 | Oral Care Compositions Comprising Spherical Fused Silica - An oral care composition comprising fused silica, wherein at least 25% of the fused silica particles are spherical. | 2010-06-03 |
20100135923 | Oral Care Compositions with Fused Silica - An oral care composition comprising a fused silica abrasive, wherein the composition has a stable viscosity. | 2010-06-03 |
20100135924 | Oral Care Compositions Comprising Fused Silica - An oral care composition comprising a fused silica abrasive and an orally-acceptable carrier. | 2010-06-03 |
20100135925 | Prophy Paste and Weekly Oral Care Compositions - An oral care composition comprising a fused silica abrasive, wherein the fused silica has a median particle size of at least about 7 microns and wherein the composition has a PCR of at least about 100. | 2010-06-03 |
20100135926 | ANTIMICROBIAL AND IMMUNOSTIMULATORY SYSTEM COMPRISING AN OXIDOREDUCTASE ENZYME - The present invention relates to an antimicrobial and immunostimulatory system, applications thereof and a process for the production of the antimicrobial and immunostimulatory system. The present invention provides a storage-stable antimicrobial and immunostimulatory system comprising an oxidoreductase enzyme, a substrate for the oxidoreductase enzyme and hydrogen peroxide in an aqueous solution wherein the substrate for the oxidoreductase enzyme is present up to 90% by weight and water is present up to 20% by weight based on the weight of the total composition; the system has a pH from approximately 4 to 8; and the system provides a two-stage hydrogen peroxide release. | 2010-06-03 |
20100135927 | Mild Oral Care Compositions - Oral compositions comprising fused silica, wherein the composition is essentially free of sodium lauryl sulfate. | 2010-06-03 |
20100135928 | Oral Care Compositions with Fused Silica - An oral care composition comprising a fused silica abrasive and a stannous ion source. | 2010-06-03 |
20100135929 | Oral Care Compositions Containing Gel Networks and Fused Silica - An oral care composition comprising a fused silica abrasive and a gel network. | 2010-06-03 |
20100135930 | Low Ph Oral Care Compositions with Fused Filica - An oral care composition comprising a fused silica abrasive and a fluoride source. The oral care composition may have a lower pH to aid in fluoride and/or active stability. | 2010-06-03 |
20100135931 | Whitening Composition with Fused Silica - An oral care composition comprising fused silica and an oxidizing agent. | 2010-06-03 |
20100135932 | Sensitivity Oral Care Compositions - An oral care composition comprising a fused silica abrasive, wherein the fused silica has a median particle size of from about 0.25 micron to about 5.0 microns. | 2010-06-03 |
20100135933 | Antibacterial Oral Care Compositions with Fused Silica - An oral care composition comprising a fused silica abrasive and an active. | 2010-06-03 |
20100135934 | Oral Care Compositions with Abrasive Combinations - An oral care composition comprising an abrasive combination of a fused silica abrasive and other abrasive selected from the group consisting of precipitated silica, calcium carbonate, rice hull silica, silica gels, aluminas, aluminium silicates, water-insoluble phosphates including orthophosphates, polymetaphosphates, pyrophosphates, other inorganic particulates, and mixtures thereof. | 2010-06-03 |
20100135935 | Composition using cross-linked hyaluronic acid for topical cosmetic and therapeutic applications - Disclosed are compositions comprising crosslinked hyaluronic acid gels, preferably vinyl sulfone cross-linked hyaluronic acid known as hylan B gel, for use in topical cosmetic and dermatological formulations. The hylan B gel in these formulations provides prolonged delivery of incorporated substances to the surface of the skin, to provide a hydrated film on the surface of the skin, and to provide a substantive and compatible film on the skin. | 2010-06-03 |
20100135936 | Delivery of hydrophobic benefit agents from bodywashes and the like onto a keratinous substrate - This invention relates to a delivery system for hydrophobic benefit agents to keratinous substrates. The delivery system comprises amphiphilic block copolymers, and a hydrophobic benefit agent, which amphiphilic block copolymers comprise a siloxane segment and a cationic segment. The invention also relates to methods of delivering the hydrophobic benefit agents to the keratinous substrate. Furthermore, the delivery systems and methods of delivery are effective in retaining an hydrophobic benefit agents on the keratinous substrate after rinsing. | 2010-06-03 |
20100135937 | METAL OXIDE NANOCRYSTALS: PREPARATION AND USES - Nanocrystalline forms of metal oxides, including binary metal oxide, perovskite type metal oxides, and complex metal oxides, including doped metal oxides, are provided. Methods of preparation of the nanocrystals are also provided. The nanocrystals, including uncapped and uncoated metal oxide nanocrystals, can be dispersed in a liquid to provide dispersions that are stable and do not precipitate over a period of time ranging from hours to months. Methods of preparation of the dispersions, and methods of use of the dispersions in forming films, are likewise provided. The films can include an organic, inorganic, or mixed organic/inorganic matrix. The films can be substantially free of all organic materials. The films can be used as coatings, or can be used as dielectric layers in a variety of electronics applications, for example as a dielectric material for an ultracapacitor, which can include a mesoporous material. Or the films can be used as a high-K dielectric in organic field-effect transistors. In various embodiments, a layered gate dielectric can include spin-cast (e.g., 8 nm-diameter) high-K BaTiO | 2010-06-03 |
20100135938 | Oil-In-Water Emulsion Composition And Method For Producing The Same - The present invention provides an oil-in-water emulsion composition having excellent emulsion stability, low sticky feeling, and low skin irritation. The oil-in-water emulsion composition according to the present invention comprising (a) 1 to 20 mass % of a powder component, (b) 0.001 to 0.5 mass % of a cationic surfactant having two alkyl chains with 12 or more and 22 or less carbon atoms, (c) an oil phase component, and (d) a water phase component, having a structure wherein (a) powder particles are adsorbed on the oil droplets dispersed in the water phase. | 2010-06-03 |
20100135939 | UV LIGHT-PROTECTIVE AGENT BASED ON MIXED INORGANIC-ORGANIC SYSTEMS - The present invention relates to photoprotective preparations, in particular in the field of cosmetics, based on inorganic-organic mixed systems. The present invention relates in particular to photoprotective preparations comprising nanoparticles of at least one metal derivative, at least one photoprotective compound chemically bonded to these metal derivative nanoparticles, and at least one further organic UV photoprotective agent which is different from the photoprotective compound bonded to the metal derivative nanoparticles. | 2010-06-03 |
20100135940 | SEMI-CRYSTALLINE SUPRAMOLECULAR POLYMERS - The invention relates to a supramolecular polymer derived from the reaction between (i) an amine bearing a nitrogen-containing heterocyclic group: imidazolidone, trimethyleneurea or triazine, capable of joining together via hydrogen bonds with (ii) at least one fatty acid monomer comprising at least one reactive functional group, a dimer of identical or different fatty acids and/or a trimer of identical or different fatty acids, or a derivative of said fatty acid(s) chosen from a fatty acid ester, and a fatty acid chloride. | 2010-06-03 |
20100135941 | SKIN-WHITENING AGENT - A skin-whitening agent offering an excellent whitening effect and being effective in preventing and treating age spots, freckles, etc., where such skin-whitening agent contains as its effective ingredient a whey protein hydrolyzate characterized by a molecular weight distribution of 10 kDa or less, main peak of 200 Da to 3 kDa, APL (average peptide-chain length) of 2 to 8, free amino acid content of 20% or less, and antigenicity of one-ten thousandth of β-lactoglobulin or less, as well as a cosmetic, drink or food, feed, pharmaceutical preparation or other skin-whitening product containing such skin-whitening agent. | 2010-06-03 |
20100135942 | Depigmenting keratin materials utilizing dithiolane compounds - A cosmetic regime or regimen for depigmenting, lightening and/or bleaching keratin materials, especially the skin, entails topically applying thereon a cosmetic composition containing a dithiolane compound of formula (I): | 2010-06-03 |
20100135943 | SKIN LIGHTENING COMPOSITIONS - A skin lightening composition is provided which comprises components (a) a flavanoid, (b) vitamin C and (c) vitamin E wherein at least component (b) is provided in a form suitable for systemic administration with the other components being provided | 2010-06-03 |
20100135944 | METHODS FOR DARKENING THE SKIN AND/OR HAIR - The present invention relates to a method of darkening the skin or hair by topically applying thereto a skin-darkening effective amount of a lotus leaf extract. | 2010-06-03 |
20100135945 | GYMNEMA-CONTAINING LIP BALM COMPOSITIONS AND ASSOCIATED METHODS - Extracts of members of the plant family Asclepiadaceae can alter or diminish a person's ability to taste some sugars. As such, the extracts can be used help a person reduce their caloric intake and thereby reduce their body weight or body fat percentage. An extract of the plant | 2010-06-03 |
20100135946 | METHOD OF TREATING HAIR WITH A SUGAR COMPOSITION - A hair treatment composition comprising: i) a sugar comprising from three to four waters of crystallisation, esp. lactulose; ii) at least one further ingredient selected from the group consisting of a suitable carrier, a styling polymer or a surfactant. | 2010-06-03 |
20100135947 | HAIR CONDITIONING COMPOSITIONS - The invention provides a hair conditioning composition comprising a cationic surfactant, a fatty material, a poly-galactomannan having hydrophilic and hydrophobic substituents, and an aqueous carrier. Compositions of the invention provide a superior viscosity profile. | 2010-06-03 |
20100135948 | Anti-Autoimmune Antibodies for Treatment of Pemphigus - This invention relates to compositions and methods for the use of anti-autoimmune reagents that specifically bind to anti-desmoglein antibodies, which are responsible for both pemphigus vulgaris and pemphigus foliaceus. In addition, the invention relates to methods and compositions for inhibiting the expression or function of a variable region of an anti-desmoglein (anti-Dsg) pathogenic autoantibody. | 2010-06-03 |
20100135949 | ANTIMICROBIAL COMPOSITIONS - Antimicrobial compositions and methods are disclosed. The antimicrobial compositions are particularly useful in providing antimicrobial capability to a wide-range of medical devices. In one aspect the invention relates a UV curable antimicrobial coating comprising a UV curable composition comprising an oligomer, a momoner, and a photoinitiator which are together capable of forming a UV curable polymer composition. The compositions include rheology modifiers as necessary. The compositions also include antimicrobial agents, which may be selected from a wide array of agents. Representative antimicrobial agents include cetyl pyridium chloride, cetrimide, alexidine, chlorexidine diacetate, benzalkonium chloride, and o-phthalaldehyde. | 2010-06-03 |
20100135950 | Iron(II)-Containing Treatments for Hyperphosphatemia - A pharmaceutical composition comprises a pharmaceutically acceptable ferrous iron compound; an amine polymer or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. Alternatively, a pharmaceutical composition comprises a pharmaceutically acceptable ferrous iron compound and pharmaceutically acceptable carrier, wherein the ferrous iron compound is selected from the group consisting of iron(II) acetate, iron(II) citrate, iron(II) ascorbate, iron(II) oxalate, iron(II) oxide, iron(II) carbonate, iron(II) carbonate saccharated, iron(II) formate, iron(II) sulfate, iron(II) chloride, iron(II) acetylacetonate and combinations thereof. A method of treating a subject with hyperphosphatemia comprises administering to the subject an effective amount of a pharmaceutical composition as described above. | 2010-06-03 |
20100135951 | Agents and Methods Related to Reducing Resistance To Apoptosis-Inducing Death Receptor Agonists - Provided herein is a method of reversing or preventing a target cell's resistance to a death receptor agonist. Also provided are methods of screening for biomarkers resistance of and monitoring resistance to death receptor agonists. Also provided are methods of selectively inducing apoptosis in a target cell, treating a subject with cancer, autoimmune or inflammatory diseases, comprising administering compositions provided herein. Further provided are compositions comprising agents that modulate CARD containing proteins. | 2010-06-03 |
20100135952 | METHODS FOR THE TREATMENT OF RENAL FAILURE - The present invention relates to methods for treating renal failure. Particularly, the present invention relates to methods for treating renal failure by administering to a subject complexes that include a member of the IL-6 family linked to a soluble receptor of the member of the IL-6 family, or isolated polynucleotides encoding same, the complexes capable of activating a gp130 mediated signaling pathway, thereby treating acute or chronic renal failure. | 2010-06-03 |
20100135953 | Method of treatment of age-related macular degeneration - The invention provides methods and compositions for treatment of age-related macular degeneration, which comprises causing T cells that produce IL-4 to accumulate in the eye by administration of an agent such as Copolymer-1, IL-4, cells activated with IL-4, IL-13 or up to 20 ng/ml IFN-g, or a pathogenic self-antigen associated with a T-cell-mediated specific autoimmune disease of the eye or a peptide derived therefrom, and any combination of such agents. | 2010-06-03 |
20100135954 | 6-Phenylpyrimidinones as PIM Modulators - A compound having Formula I or II (Formula I) or (Formula II), or a pharmaceutically acceptable salt thereof, wherein X, Z, R | 2010-06-03 |
20100135955 | HUMAN M2e PEPTIDE IMMUNOGENS - The present invention provides novel peptide immunogens comprising influenza virus matrix 2 protein epitopes and related compositions and methods. The present invention relates to a composition comprising a peptide immunogen useful for the prevention and treatment of an influenza virus-mediated disease. The invention also relates to vaccines, immunogenic products and immunogenic compositions containing the peptide immunogens. | 2010-06-03 |
20100135956 | STEROID MODULATORS OF PROGESTERONE RECEPTOR AND/OR GLUCOCORTICOID RECEPTOR - The present invention relates to new steroid modulators of progesterone receptor activity and/or glucocorticoid receptor activity, pharmaceutical compositions thereof, and methods of use thereof. | 2010-06-03 |
20100135957 | Chimeric Heteromultimer Adhesins - Novel chimeric heteromultimer adhesins that bind the ligand of natural heteromultimeric receptors and uses therefor are disclosed. The chimeric molecules of the heteromultimer adhesins comprise an extracellular domain of a heteromultimeric receptor monomer and a multimerization domain for the stable interaction of the chimeric molecules in the adhesin. Specifically disclosed are heteromultimeric adhesins comprising the extracellular domains of ErbB2 and ErbB3 or ErbB2 and ErbB4. The chimeric ErbB heteromultimer adhesins of the present invention are useful as competitive antagonists or agonists of a neuregulin for the treatment of diseases such as various cancers. | 2010-06-03 |
20100135958 | METHOD FOR TREATING CANCER IN HUMANS - A method of treating and/or preventing cancer in a subject, preferably mammalian, more preferably human, by administering in an effective amount IL-21 polypeptide, polynucleotide, vector comprising an IL-21 nucleic acid sequence encoding an IL-21 polypeptide, variants, and fragments thereof, thereby acting as an anti-cancer agent by reducing, ameliorating, and/or eliminating the cancer; and a method of treating and/or preventing cancer in a subject by co-administering the IL-21 polypeptide, polynucleotide, IL-21 vector, variant, and fragments thereof, with an immunotherapeutic and/or chemotherapeutic agent for the treatment and/or prevention of cancer in a subject. | 2010-06-03 |
20100135959 | Human Interferon Molecules and Their Uses - Modified human interferon polypeptides and uses thereof are provided. | 2010-06-03 |
20100135960 | ANTIVIRAL ACYLSULFONAMIDE DERIVATIVES - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 2010-06-03 |
20100135961 | LIVE BACTERIAL VACCINES RESISTANT TO CARBON DIOXIDE (CO2), ACIDIC PH AND/OR OSMOLARITY FOR VIRAL INFECTION PROPHYLAXIS OR TREATMENT - The present invention relates to gram-negative bacterial mutants resistant to one or more stress conditions, including, but not limited to, CO | 2010-06-03 |
20100135962 | Novel Bacteriophage and Antibacterial Composition Comprising the Same - The present invention relates to a novel bacteriophage, more particularly, a bacteriophage that has a specific bactericidal activity against Fowl Typhoid causing | 2010-06-03 |
20100135963 | USE OF PAX4 IN PANCREATIC CELL PROLIFERATION - The present invention relates to an in vitro method for the generation and isolation of pancreatic β-cells, comprising the steps of (a) contacting an adult cell derived from mammalian pancreatic islets or an explant culture of adult pancreatic islets with functional, wild-type Pax4; and (b) detecting and isolating; from said adult cell or explant culture, β-cells that proliferate in response to the contact with Pax4. Furthermore, the use of functional; wild-type Pax4 for the preparation of a pharmaceutical composition for transplantation and/or tissue replacement is described. | 2010-06-03 |
20100135964 | TISSUE GRAFTING METHOD - The tissue grafting method relates to a tissue graft material, a method of preparing the material, and a method of using the material. The tissue graft material is made from the tunica serosa of the small intestine of a warm-blooded vertebrate, which has been delaminated from the tunica muscularis, tunica submucosa, and the tunica mucosa of the intestinal tissue. The tissue graft material may be perforated by discrete punctures. The tissue graft material is dehydrated by air drying or vacuum drying, sterilized with ethylene oxide, and stored in a hermetically sealed enclosure at room temperature until needed, having an indefinite storage life. When needed, the tissue graft material is rehydrated, cut to match the size of the wound, and applied to the wound. The graft may be overlaid with nylon mesh, or bandaged with an elastic tubular dressing. | 2010-06-03 |
20100135965 | METHOD OF CHONDROGENIC DIFFERENTIATION FROM MESENCHYMAL STEM CELL, AND COMPOSITION COMPRISING CHONDROGENIC CELL DIFFERENTIATED USING THE METHOD TO TREAT DISEASE CAUSED BY CARTILAGE DAMAGE - Provided are a method of chondrogenic differentiation from mesenchymal stem cells and a composition comprising chondrogenic cells differentiated using the method to treat diseases caused by cartilage damage. In the method, a centrifugal force is applied to human mesenchymal stem cells to be differentiated into chondrogenic cells. The chondrogenic differentiation may be achieved at moderate cost without using expensive cytokines or growth factors by periodically applying only a centrifugal force. According to the method of chondrogenic differentiation from mesenchymal stem cells in the present embodiment, chondrogenic cells may be also differentiated from human mesenchymal stem cells. | 2010-06-03 |
20100135966 | AGENTS FOR TREATING FLAVIVIRIDAE INFECTIONS - The invention relates to agents for the treatment, therapy and inhibition of Flaviviridae virus infections, which agents comprise proteasome inhibitors as the active component. The agents which are used for inhibiting the release, maturation and replication of Flaviviridae comprise, as the active component in pharmaceutical preparations, substance classes which share the common property of inhibiting the 26S proteasome in cells. These substance classes include, in particular, proteasome inhibitors which affect the activities of the ubiquitin/proteasome pathway, in particular the enzymic activities of the 26S and the 20S proteasome complex. The application of the invention lies in the antiviral therapy of Flaviviridae infections, especially in preventing the establishment and maintenance of a chronic hepatitis C virus infection and a hepatopathogenesis which is associated therewith. | 2010-06-03 |
20100135967 | CULTURED CARTILAGE/BONE CELLS/TISSUE, METHOD OF GENERATING SAME AND USES THEREOF - A method of generating cultured chondrocytes/endochondral bone cells is provided. The method comprising isolating chondrocytes from mandibular condyle tissue, and culturing the isolated chondrocytes. A method of isolating chondrocytes from mandibular condyle tissue is further provided. The method comprises isolating mandibular condyle tissue from a mammal and treating the mandibular condyle tissue so as to selectively remove fibroblast-like cells and/or myocytes therefrom, the modified mandibular condyle tissue including chondrocytes, and selectively collecting the chondrocytes from the modified mandibular condyle tissue. | 2010-06-03 |
20100135968 | Oligodendrocyte Production From Multipotent Neural Stem Cells - This invention relates to methods of producing oligodendrocytes from multipotent neural stem cells by using at least one oligodendrocyte promoting factor, particularly granulocyte-macrophage colony stimulating factor, granulocyte colony stimulating factor, interleukin 3 or interleukin 5. The neural stem cells may optionally be expanded prior to being subjected to the oligodendrocyte promoting factor. | 2010-06-03 |
20100135969 | METHOD OF TREATING CANCER USING PLATELET RELEASATE - Platelets are concentrated from the blood of a patient. The platelets are treated by a method such as ultrasound or agitation to obtain platelet releasate. This releasate as a whole or a component thereof is formulated into an injectable formulation which is administered to the same patient the platelets were extracted from in order to treat the patient's cancer. | 2010-06-03 |
20100135970 | Methods for Reprogramming Adult Somatic Cells and Uses Thereof - As described below, the present invention features methods for reprogramming somatic cells and related therapeutic compositions and methods. | 2010-06-03 |
20100135971 | PROBIOTICS IN A PRE- AND/OR POST SURGICAL ENVIRONMENT - The present invention relates generally to the field of nutrition, more particularly to the use of probiotics in nutrition. In particular the present invention relates to the use of a probiotic or of a mixture of probiotics in the manufacture of a nutritional composition or a medicament to act the colon in a pre- or post surgical environment. | 2010-06-03 |
20100135972 | Control of Sucking Lice - The invention describes the use of a microbial preparation of one or more bacteria, for example of the genus | 2010-06-03 |
20100135973 | Microorganism Strain CRC2631 of Salmonella typhimurium and its Use as a Cancer Therapeutic - The present invention provides a biologically pure isolate of the genus | 2010-06-03 |
20100135974 | REDIRECTED, GENETICALLY-ENGINEERED T REGULATORY CELLS AND THEIR USE IN SUPPRESSION OF AUTOIMMUNE AND INFLAMMATORY DISEASE - A redirected Treg cell is endowed with specificity toward a selected target antigen or ligand. The cell contains a chimeric receptor polypeptide that is expressed in a single, continuous chain, with an extracellular recognition region displayed on the surface of the cell, a transmembrane region and an intracellular signaling region. The extracellular recognition region is specific for the selected target antigen or ligand. The intracellular signaling region includes a combination of T-cell signaling polypeptide moieties, which combination, upon binding of the extracellular recognition region to the selected target antigen or ligand, triggers activation of the redirected Treg cells to cause suppression of T-cell mediated immunity. Such redirected Treg cells may be used to suppress undesired activity of T effector cells thereby mediating an immune or inflammatory response. They are particularly useful in treating T effector cell-mediated diseases, such as inflammatory bowel disease, transplant rejection and GVH disease. | 2010-06-03 |
20100135975 | CD133 Epitopes - An immunogen includes an isolated peptide of 800 amino acid residues or fewer having the amino sequence ILSAFSVYV (SEQ ID NO:1) with four or fewer amino acid substitutions, a superagonist variant of SEQ ID NO:1, or an amino acid sequence having the formula: (I/K/T/V/M)-L-(S/L)-(A/E/N/D/Q)-(F/V)-(S/M/V/I)-(V/D/R/G/H)-Y-(V/I/L) (SEQ ID NO:13). The immunogens can be used in compositions and in the treatment of disorders. | 2010-06-03 |
20100135976 | ADSORPTION DEVICE - The invention relates to an adsorption device for removal and/or reduction of undesirable components from blood, such as whole blood, comprising, porous cross-linked polysaccharide particles or beads, wherein the particles or beads have an average size from about 210±50 μm, at least 30% of the particles have a size from about 180 to about 240 μm, at least 70% of the particles have a size from about 150 to about 300 μm and said particles have at least one immobilised ligand, wherein said immobilised ligand have a size of about 150 kD or less. The invention also relates to kits comprising said adsorption device as well as the use of said adsorption device in different applications such as cleaning of blood. | 2010-06-03 |
20100135977 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISEASES - A pharmaceutical composition for treating a metabolic disease in a mammalian subject includes a therapeutically effective amount of all-trans-13,14-dihydroretinoid, all-trans-13,14-dihydroretinoid derivative, or agent capable of modulating the level of at least one all-trans-13,14-dihydroretinoid or all-trans-13,14-dihydroretinoid derivative in the subject. | 2010-06-03 |
20100135978 | Proteases for Pharmaceutical Use - The pharmaceutical use of proteases related to amino acids 1-274 of SEQ ID NO: 2, the serine protease derived from | 2010-06-03 |
20100135979 | STABILIZED SUSPENSION - A stabilized, colloidal free radical reduced aqueous suspension containing a complex of amorphous Hyaluronic acid (HA) with a mean molecular weight (mean MW) in the range of 80 to 400 kDa and amorphous protein drug, such as insulin, glucagon-like peptide 1 (GLP1), human growth hormone (hGH), erythropoietin (EPO) and super oxide dismutase (SOD), and an excess amount of HA, for example a HA with a mean MW of 6-15 kDa, to minimize the water-content, is described. The composition may additionally comprise HA with a mean MW in the range between 1 and 8 kDa when it is in lyophilized free-flowing powder form. Further, a pharmaceutical composition comprising the suspension and a method of producing the suspension including production of amorphous hyaluronic acid and amorphous protein, are disclosed. The pharmaceutical composition is intended for oral as well as parenteral administration. | 2010-06-03 |
20100135980 | Therapeutic and prophylactic uses of cell specific carbonic anhydrase enzymes in treating aging, disorders of aging, cancer, as growth factors, and as an alternative to stem cell therapy - A method for the treatment and prophylaxis of diseases or conditions associated with aging which includes oxidative stress and cancer. Such diseases or conditions are associated with a decrease or increase presence of one or a combination of one or more Carbonic Anhydrase isozymes I TO VII in the tissue of a subject. These diseases include but are not limited to chronic neurodegenerative diseases such as Alzheimer's disease, parkinson's disease, multiple sclerosis, autism, lou gehrig's disease, huntington's disease, immune disorders which includes systemic lupus erythematosus, diabetes mellitus; musculo-skeletal disorders which includes osteoporosis,arthritis, osteomalacia. Cancer which includes the breast, lung, colon, prostate gland, ovary, esophagus, liver, rectum. The method comprises administering to the patient a pharmaceutically effective non toxic amount of one or a combination of one or more compounds that increases or decreases the level of one or more Cell Specific Carbonic Anhydrase Enzymes whose levels have been increased or decreased in the tissue of the subject. Such compound maybe the Cell Specific Carbonic Anhydrase Enzymes I to VII. A compound that when absorbed reacts or dissociates to form cell specific carbonic enzymes or one or more compounds that when administered promotes the increase or decrease level of one or more cell specific Carbonic anhydrase I,II,III,IV,V,VI,VII. As growth factors of stem cells as an alternative to stem cell therapy. These methods includes the administering of one or a combination of one or more of these compounds over an extended period of time ranging from 6 months until the patient dies. | 2010-06-03 |
20100135981 | USE OF THE ENDOGLYCOSIDASE ENDOS FOR TREATING IMMUNOGLOBULIN G MEDIATED DISEASES - The invention provides use of an EndoS polypeptide, or a polynucleotide encoding an EndoS polypeptide, in the manufacture of a medicament for the treatment or prevention of a disease or condition mediated by IgG antibodies. | 2010-06-03 |
20100135982 | SIMETHICONE SOLID ORAL DOSAGE FORM - The present invention provides a composition for forming a compressed solid dosage form that is a free-flowing compressible admixture of simethicone, an adsorbant, and an optional active agent, wherein the weight ratio of simethicone to adsorbent is at least 1:2.22. Also included are solid dosage forms made from a free-flowing compressible admixture of simethicone, an adsorbant, and an optional active agent, wherein the weight ratio of simethicone to adsorbent is at least 1:2.22. | 2010-06-03 |
20100135983 | Anti-inflammatory compositions and methods - Certain embodiments disclosed relate to compositions, including therapeutic compositions, methods, devices, and systems that modulate at least one inflammatory response or reaction. According to various embodiments, the compositions, methods, devices, and systems relate to modulating one or more of Toll-like receptors, Src family kinases, NF-kB molecules, proteases, or proteasomes. | 2010-06-03 |
20100135984 | Anti-inflammatory compositions and methods - Certain embodiments disclosed relate to compositions, including therapeutic compositions, methods, devices, and systems that modulate at least one inflammatory response or reaction. According to various embodiments, the compositions, methods, devices, and systems relate to modulating one or more of Toll-like receptors, Src family kinases, NF-kB molecules, proteases, or proteasomes. | 2010-06-03 |